Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Amortization of Deferred Charges: 2024-2025

Historic Amortization of Deferred Charges for Arrowhead Pharmaceuticals (ARWR) over the last 2 years, with Sep 2025 value amounting to $63.3 million.

  • Arrowhead Pharmaceuticals' Amortization of Deferred Charges rose 56.18% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.3 million, marking a year-over-year change of. This contributed to the annual value of $63.3 million for FY2025, which is 579.67% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Amortization of Deferred Charges of $63.3 million as of FY2025, which was up 579.67% from $9.3 million recorded in FY2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Amortization of Deferred Charges peaked at $63.3 million during FY2025, and registered a low of $9.3 million during FY2024.
  • For the 2-year period, Arrowhead Pharmaceuticals' Amortization of Deferred Charges averaged around $36.3 million, with its median value being $36.3 million (2024).
  • Data for Arrowhead Pharmaceuticals' Amortization of Deferred Charges shows a peak YoY skyrocketed of 579.67% (in 2025) over the last 5 years.
  • Over the past 2 years, Arrowhead Pharmaceuticals' Amortization of Deferred Charges (Yearly) stood at $9.3 million in 2024, then spiked by 579.67% to $63.3 million in 2025.